ST-segment elevation myocardial infarction (STEMI) is most commonly caused by an acute occlusion of a coronary blood vessel secondary to acute plaque rupture and thrombosis. The treatment goal for STEMI is rapid reperfusion via coronary interventions which are linked with high risk. Dual antiplatelet therapy (DAPT), using a combination of aspirin and a P2Y12 inhibitor, can cause a significant prognostic improvement in patients with acute coronary syndrome (ACS) and is associated with a lower risk of long-term atherothrombotic events, like stent thrombosis and myocardial infarction. To gain more insights, please join the experts Dr.
Sridhar Kasturi and Dr. Shailender Singh , as they will be discussing on High risk coronary interventions during STEMI and impact of DAPT in high risk ACS, respectively. Access 360 and Docplexus have organized a webinar on 8th June, 2020, Monday from 1.00 to…
